Testagen

Testagen is a synthetic tetrapeptide — Lys-Glu-Asp-Gly (KEDG) — from the Khavinson group's designed "Cytogen" short-peptide family, researched for testicular-tissue-targeted bioregulation, reproductive endocrine function, and testosterone-pathway support. It is one of the synthesized Khavinson compounds with a defined three-amino-acid sequence. Testagen is not approved by the FDA, EMA, or any major Western regulator and is sold as a research-use-only compound by third-party laboratories. Notably, Testagen (Lys-Glu-Asp-Gly) and Vesugen (Lys-Glu-Asp) share the same first three residues, but they are not the same compound: Testagen carries an extra C-terminal glycine. Because that glycine adds roughly 57 Da, mass spectrometry distinguishes the two — the shared core is a labeling-confusion risk, not a molecular identity.

Source: Short Peptides Regulate Gene Expression, Khavinson V.Kh., Linkova N.S., Tarnovskaya S.I. (optional, non-blocking follow-up: confirm full author list), Bulletin of Experimental Biology and Medicine, 2016

What is Testagen and how does the testicular bioregulatory mechanism work?

Testagen is a synthetic Lys-Glu-Asp-Gly tetrapeptide proposed to enter testicular cell nuclei and modulate gene expression in pathways related to spermatogenesis, Leydig cell function, and reproductive endocrine signaling. Within the Khavinson framework, Testagen is the testicular-targeted bioregulator complement to other organ-specific compounds. Notably, its first three residues (Lys-Glu-Asp) are the whole Vesugen tripeptide, which Testagen extends by a C-terminal glycine (see the comparison below); the two are related but not identical, and the Khavinson framework's assignment of Testagen to testicular tissue is a proposal, not established biology — the Khavinson framework attributes tissue specificity to context-dependent effects rather than sequence differences in this case.

Evidence level: Preclinical; Khavinson-group research; independent replication limited

What does the research show for Testagen?

The published work on Testagen comes almost entirely from one group — Vladimir Khavinson's, at the St Petersburg Institute of Bioregulation and Gerontology — and is preclinical (gene-expression and cell/rodent models); reported effects on spermatogenesis and reproductive endocrine markers are single-institution and non-blinded. Human clinical research at FDA-grade Phase 2/3 standards has not been conducted. No Western-standard randomized controlled trial of Testagen has been published as of August 2026, and independent replication outside this group is limited.

Evidence level: Preclinical; Khavinson-group research; FDA-grade Phase 2/3 not conducted

How does Testagen compare to other Khavinson bioregulators?

Testagen sits in the reproductive-endocrine subset alongside other organ-targeted bioregulators, with its notable feature being the C-terminal glycine that distinguishes it from the otherwise identical Vesugen tripeptide.

What are the documented side effects of Testagen?

Side effects in available preclinical data and community-reported research use are mild — injection-site reactions are the most common report. Long-term safety in humans at sustained research-use dosing is not characterized at Western clinical standards.

Evidence level: preclinical safety; human long-term unestablished

What is the regulatory status of Testagen?

Testagen is not approved by the FDA, EMA, or any major Western regulator as of August 2026. Testagen is not on the FDA's active Section 503A/503B Category-2 bulk-substances list and was not among the peptides addressed in the FDA's April 2026 Category-2 actions or the July 2026 Pharmacy Compounding Advisory Committee meeting — no U.S. compounding pathway applies to it. Regulatory context in FDA peptide regulation 2025–2026 timeline.

Source: FDA 503A bulk drug substances (Category 1/2) page

Why does Testagen vendor verification matter — and how it differs from Vesugen?

Testagen (Lys-Glu-Asp-Gly) and Vesugen (Lys-Glu-Asp) share a three-residue core but are distinct molecules — Testagen has an extra C-terminal glycine (~57 Da). Mass spectrometry can tell them apart, which is exactly why a batch-matched mass-spec identity check matters here: it confirms you received the four-residue Testagen and not the shorter Vesugen mislabeled under another name. This is a structural issue with the Khavinson naming convention rather than a vendor-quality issue. Independent HPLC purity testing remains the standard quality signal. Guidance in how-to-test-peptides hub.

How does Peptigrity verify Testagen vendors?

Peptigrity collects independent third-party Certificates of Analysis for Testagen from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. The Testagen-vs-Vesugen distinction (a C-terminal glycine, ~57 Da) is flagged in our verification framework so a mass-spec check confirms the correct peptide. Methodology in how we calculate trust scores.

Frequently asked questions

What does Testagen do?

Testagen is proposed to act on testicular tissue and reproductive endocrine function through epigenetic gene-expression modulation. Human Phase 2/3 efficacy is not established at Western clinical standards.

Is Testagen the same compound as Vesugen?

No. Vesugen is the tripeptide Lys-Glu-Asp; Testagen is the tetrapeptide Lys-Glu-Asp-Gly — the same three residues plus a C-terminal glycine. They are related but chemically distinct, differ by about 57 Da, and mass spectrometry can distinguish them. The Khavinson framework attributes their different proposed tissue targets to context-dependent effects.

Source: Short Peptides Regulate Gene Expression, Khavinson V.Kh., Linkova N.S., Tarnovskaya S.I. (optional, non-blocking follow-up: confirm full author list), Bulletin of Experimental Biology and Medicine, 2016

Is Testagen legal to purchase?

Testagen is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption in the US, EU, or most Western markets. Country breakdown in peptide legal status guide.

Will Testagen be FDA-approved?

No active FDA approval pathway exists for Testagen as of August 2026.

How can I verify a Testagen vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. Note that mass spectrometry distinguishes Testagen (Lys-Glu-Asp-Gly) from the shorter Vesugen (Lys-Glu-Asp) by the ~57 Da C-terminal glycine, so a batch-matched mass-spec identity check plus HPLC purity is the objective test. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a Testagen dose?

No. Testagen is not approved for human consumption in Western jurisdictions and Peptigrity is an independent review platform, not a medical authority. Anyone considering use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. Testagen is not approved by the FDA or any major Western regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.